Cargando…
Resistance to HER2-targeted anti-cancer drugs is associated with immune evasion in cancer cells and their derived extracellular vesicles
Neuromedin U (NmU) -a neuropeptide belonging to the neuromedin family– plays a substantial role in HER2-positive breast cancer, correlating with increased aggressiveness, resistance to HER2-targeted therapies and overall significantly poorer outcome for patients. However, the mechanism through which...
Autores principales: | Martinez, Vanesa G., O'Neill, Sadhbh, Salimu, Josephine, Breslin, Susan, Clayton, Aled, Crown, John, O'Driscoll, Lorraine |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Taylor & Francis
2017
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5706614/ https://www.ncbi.nlm.nih.gov/pubmed/29209569 http://dx.doi.org/10.1080/2162402X.2017.1362530 |
Ejemplares similares
-
miR-630 targets IGF1R to regulate response to HER-targeting drugs and overall cancer cell progression in HER2 over-expressing breast cancer
por: Corcoran, Claire, et al.
Publicado: (2014) -
2-Deoxy-D-Glucose inhibits aggressive triple-negative breast cancer cells by targeting glycolysis and the cancer stem cell phenotype
por: O’Neill, Sadhbh, et al.
Publicado: (2019) -
A method of separating extracellular vesicles from blood shows potential clinical translation, and reveals extracellular vesicle cargo gremlin-1 as a diagnostic biomarker
por: McNamee, Niamh, et al.
Publicado: (2021) -
Neratinib resistance and cross-resistance to other HER2-targeted drugs due to increased activity of metabolism enzyme cytochrome P4503A4
por: Breslin, Susan, et al.
Publicado: (2017) -
miR-758-3p: a blood-based biomarker that’s influence on the expression of CERP/ABCA1 may contribute to the progression of obesity to metabolic syndrome
por: O’Neill, Sadhbh, et al.
Publicado: (2018)